Download PDF
Semin Liver Dis 2010; 30(4): 402-410
DOI: 10.1055/s-0030-1267540
© Thieme Medical Publishers

Apoptosis as a Mechanism for Liver Disease Progression

Maria Eugenia Guicciardi1 , Gregory J. Gores1
  • 1Division of Gastroenterology and Hepatology, College of Medicine, Mayo Clinic, Rochester, Minnesota
Further Information

Publication History

Publication Date:
19 October 2010 (online)

    Permissions and Reprints

ABSTRACT

Hepatocyte injury is ubiquitous in clinical practice, and the mode of cell death associated with this injury is often apoptosis, especially by death receptors. Information from experimental systems demonstrates that hepatocyte apoptosis is sufficient to cause liver hepatic fibrogenesis. The mechanisms linking hepatocyte apoptosis to hepatic fibrosis remain incompletely understood, but likely relate to engulfment of apoptotic bodies by professional phagocytic cells and stellate cells, and release of mediators by cells undergoing apoptosis. Inhibition of apoptosis with caspase inhibitors has demonstrated beneficial effects in murine models of hepatic fibrosis. Recent studies implicating Toll-like receptor 9 in liver injury and fibrosis are also of particular interest. Engulfment of apoptotic bodies is one mechanism by which the TLR9 ligand (CpG DNA motifs) could be delivered to this intracellular receptor. These concepts suggest therapy focused on interrupting the cellular mechanisms linking apoptosis to fibrosis would be useful in human liver diseases.

KEYWORDS

Bcl-2 proteins - caspase inhibitors - death receptors - stellate cells - Toll-like receptor 9

REFERENCES

  • 1 Kim W R, Flamm S L, Di Bisceglie A M, Bodenheimer H C. Public Policy Committee of the American Association for the Study of Liver Disease . Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease.  Hepatology. 2008;  47(4) 1363-1370
    CrossrefPubMedGoogle Scholar
  • 2 Rust C, Gores G J. Apoptosis and liver disease.  Am J Med. 2000;  108(7) 567-574
    CrossrefPubMedGoogle Scholar
  • 3 Canbay A, Friedman S, Gores G J. Apoptosis: the nexus of liver injury and fibrosis.  Hepatology. 2004;  39(2) 273-278
    CrossrefPubMedGoogle Scholar
  • 4 Kerr J F, Wyllie A H, Currie A R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.  Br J Cancer. 1972;  26(4) 239-257
    CrossrefPubMedGoogle Scholar
  • 5 Grassi A, Susca M, Ferri S et al.. Detection of the M30 neoepitope as a new tool to quantify liver apoptosis: timing and patterns of positivity on frozen and paraffin-embedded sections.  Am J Clin Pathol. 2004;  121(2) 211-219
    CrossrefPubMedGoogle Scholar
  • 6 Pop C, Salvesen G S. Human caspases: activation, specificity, and regulation.  J Biol Chem. 2009;  284(33) 21777-21781
    CrossrefPubMedGoogle Scholar
  • 7 Oberst A, Pop C, Tremblay A G et al.. Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation.  J Biol Chem. 2010;  285(22) 16632-16642
    CrossrefPubMedGoogle Scholar
  • 8 Canbay A, Feldstein A, Baskin-Bey E, Bronk S F, Gores G J. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse.  J Pharmacol Exp Ther. 2004;  308(3) 1191-1196
    CrossrefPubMedGoogle Scholar
  • 9 Wieckowska A, Zein N N, Yerian L M, Lopez A R, McCullough A J, Feldstein A E. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease.  Hepatology. 2006;  44(1) 27-33
    CrossrefPubMedGoogle Scholar
  • 10 Taylor R C, Cullen S P, Martin S J. Apoptosis: controlled demolition at the cellular level.  Nat Rev Mol Cell Biol. 2008;  9(3) 231-241
    CrossrefPubMedGoogle Scholar
  • 11 Malhi H, Guicciardi M E, Gores G J. Hepatocyte death: a clear and present danger.  Physiol Rev. 2010;  90(3) 1165-1194
    CrossrefPubMedGoogle Scholar
  • 12 Malhi H, Gores G J. Cellular and molecular mechanisms of liver injury.  Gastroenterology. 2008;  134(6) 1641-1654
    CrossrefPubMedGoogle Scholar
  • 13 Wei M C, Zong W X, Cheng E H et al.. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death.  Science. 2001;  292(5517) 727-730
    CrossrefPubMedGoogle Scholar
  • 14 Youle R J, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death.  Nat Rev Mol Cell Biol. 2008;  9(1) 47-59
    CrossrefPubMedGoogle Scholar
  • 15 Du C, Fang M, Li Y, Li L, Wang X. SMAC, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition.  Cell. 2000;  102(1) 33-42
    CrossrefPubMedGoogle Scholar
  • 16 Guicciardi M E, Gores G J. Life and death by death receptors.  FASEB J. 2009;  23(6) 1625-1637
    CrossrefPubMedGoogle Scholar
  • 17 Faubion W A, Gores G J. Death receptors in liver biology and pathobiology.  Hepatology. 1999;  29(1) 1-4
    CrossrefPubMedGoogle Scholar
  • 18 Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.  Cell. 1998;  94(4) 481-490
    CrossrefPubMedGoogle Scholar
  • 19 Li H, Zhu H, Xu C J, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.  Cell. 1998;  94(4) 491-501
    CrossrefPubMedGoogle Scholar
  • 20 Akazawa Y, Gores G J. Death receptor-mediated liver injury.  Semin Liver Dis. 2007;  27(4) 327-338
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Chisari F V. Cytotoxic T cells and viral hepatitis.  J Clin Invest. 1997;  99(7) 1472-1477
    CrossrefPubMedGoogle Scholar
  • 22 Sodeman T, Bronk S F, Roberts P J, Miyoshi H, Gores G J. Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas.  Am J Physiol Gastrointest Liver Physiol. 2000;  278(6) G992-G999
    PubMedGoogle Scholar
  • 23 Faubion W A, Guicciardi M E, Miyoshi H et al.. Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas.  J Clin Invest. 1999;  103(1) 137-145
    CrossrefPubMedGoogle Scholar
  • 24 Higuchi H, Bronk S F, Taniai M, Canbay A, Gores G J. Cholestasis increases tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity.  J Pharmacol Exp Ther. 2002;  303(2) 461-467
    CrossrefPubMedGoogle Scholar
  • 25 Natori S, Rust C, Stadheim L M, Srinivasan A, Burgart L J, Gores G J. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis.  J Hepatol. 2001;  34(2) 248-253
    CrossrefPubMedGoogle Scholar
  • 26 Nanji A A, Jokelainen K, Fotouhinia M et al.. Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines.  Am J Physiol Gastrointest Liver Physiol. 2001;  281(6) G1348-G1356
    PubMedGoogle Scholar
  • 27 Feldstein A E, Canbay A, Angulo P et al.. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis.  Gastroenterology. 2003;  125(2) 437-443
    CrossrefPubMedGoogle Scholar
  • 28 Barreyro F J, Kobayashi S, Bronk S F, Werneburg N W, Malhi H, Gores G J. Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis.  J Biol Chem. 2007;  282(37) 27141-27154
    CrossrefPubMedGoogle Scholar
  • 29 Cazanave S C, Mott J L, Elmi N A et al.. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis.  J Biol Chem. 2009;  284(39) 26591-26602
    CrossrefPubMedGoogle Scholar
  • 30 Malhi H, Bronk S F, Werneburg N W, Gores G J. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis.  J Biol Chem. 2006;  281(17) 12093-12101
    CrossrefPubMedGoogle Scholar
  • 31 Feldstein A E, Werneburg N W, Li Z, Bronk S F, Gores G J. Bax inhibition protects against free fatty acid-induced lysosomal permeabilization.  Am J Physiol Gastrointest Liver Physiol. 2006;  290(6) G1339-G1346
    CrossrefPubMedGoogle Scholar
  • 32 Malhi H, Barreyro F J, Isomoto H, Bronk S F, Gores G J. Free fatty acids sensitise hepatocytes to TRAIL mediated cytotoxicity.  Gut. 2007;  56(8) 1124-1131
    CrossrefPubMedGoogle Scholar
  • 33 Meriden Z, Forde K A, Pasha T L et al.. Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection.  Clin Gastroenterol Hepatol. 2010;  8(3) 289-296, 296, e1–e8
    CrossrefPubMedGoogle Scholar
  • 34 Canbay A, Higuchi H, Bronk S F, Taniai M, Sebo T J, Gores G J. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis.  Gastroenterology. 2002;  123(4) 1323-1330
    CrossrefPubMedGoogle Scholar
  • 35 Jaeschke H. Inflammation in response to hepatocellular apoptosis.  Hepatology. 2002;  35(4) 964-966
    CrossrefPubMedGoogle Scholar
  • 36 Faouzi S, Burckhardt B E, Hanson J C et al.. Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway.  J Biol Chem. 2001;  276(52) 49077-49082
    CrossrefPubMedGoogle Scholar
  • 37 Chipuk J E, Moldoveanu T, Llambi F, Parsons M J, Green D R. The BCL-2 family reunion.  Mol Cell. 2010;  37(3) 299-310
    CrossrefPubMedGoogle Scholar
  • 38 Cazanave S C, Gores G J. The liver's dance with death: two Bcl-2 guardian proteins from the abyss.  Hepatology. 2009;  50(4) 1009-1013
    CrossrefPubMedGoogle Scholar
  • 39 Takehara T, Tatsumi T, Suzuki T et al.. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses.  Gastroenterology. 2004;  127(4) 1189-1197
    CrossrefPubMedGoogle Scholar
  • 40 Hikita H, Takehara T, Shimizu S et al.. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver.  Hepatology. 2009;  50(4) 1217-1226
    CrossrefPubMedGoogle Scholar
  • 41 Nagata S, Hanayama R, Kawane K. Autoimmunity and the clearance of dead cells.  Cell. 2010;  140(5) 619-630
    Google Scholar
  • 42 Nagata S. Apoptosis by death factor.  Cell. 1997;  88(3) 355-365
    CrossrefPubMedGoogle Scholar
  • 43 Canbay A, Feldstein A E, Higuchi H et al.. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression.  Hepatology. 2003;  38(5) 1188-1198
    CrossrefPubMedGoogle Scholar
  • 44 Canbay A, Taimr P, Torok N, Higuchi H, Friedman S, Gores G J. Apoptotic body engulfment by a human stellate cell line is profibrogenic.  Lab Invest. 2003;  83(5) 655-663
    CrossrefPubMedGoogle Scholar
  • 45 Jiang J X, Mikami K, Venugopal S, Li Y, Török N J. Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways.  J Hepatol. 2009;  51(1) 139-148
    CrossrefPubMedGoogle Scholar
  • 46 Elliott M R, Chekeni F B, Trampont P C et al.. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance.  Nature. 2009;  461(7261) 282-286
    CrossrefPubMedGoogle Scholar
  • 47 Gregory C. Cell biology: Sent by the scent of death.  Nature. 2009;  461(7261) 181-182
    CrossrefPubMedGoogle Scholar
  • 48 Dranoff J A, Ogawa M, Kruglov E A et al.. Expression of P2Y nucleotide receptors and ectonucleotidases in quiescent and activated rat hepatic stellate cells.  Am J Physiol Gastrointest Liver Physiol. 2004;  287(2) G417-G424
    CrossrefPubMedGoogle Scholar
  • 49 Mehal W, Imaeda A. Cell death and fibrogenesis.  Semin Liver Dis. 2010;  30(3) 226-231
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Bourd-Boittin K, Basset L, Bonnier D, L'helgoualc'h A, Samson M, Théret N. CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liver.  J Cell Mol Med. 2009;  13(8A, 8A) 1526-1535
    CrossrefPubMedGoogle Scholar
  • 51 Wasmuth H E, Zaldivar M M, Berres M L et al.. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection.  J Hepatol. 2008;  48(2) 208-215
    CrossrefPubMedGoogle Scholar
  • 52 Hotchkiss R S, Strasser A, McDunn J E, Swanson P E. Cell death.  N Engl J Med. 2009;  361(16) 1570-1583
    CrossrefPubMedGoogle Scholar
  • 53 Friedman S L. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.  Physiol Rev. 2008;  88(1) 125-172
    CrossrefPubMedGoogle Scholar
  • 54 Kiener P A, Davis P M, Starling G C et al.. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages.  J Exp Med. 1997;  185(8) 1511-1516
    CrossrefPubMedGoogle Scholar
  • 55 Chen J J, Sun Y, Nabel G J. Regulation of the proinflammatory effects of Fas ligand (CD95L).  Science. 1998;  282(5394) 1714-1717
    CrossrefPubMedGoogle Scholar
  • 56 Dranoff J A, Wells R G. Portal fibroblasts: Underappreciated mediators of biliary fibrosis.  Hepatology. 2010;  51(4) 1438-1444
    CrossrefPubMedGoogle Scholar
  • 57 Friedman S L. Mechanisms of hepatic fibrogenesis.  Gastroenterology. 2008;  134(6) 1655-1669
    CrossrefPubMedGoogle Scholar
  • 58 Jiang J X, Mikami K, Shah V H, Torok N J. Leptin induces phagocytosis of apoptotic bodies by hepatic stellate cells via a Rho guanosine triphosphatase-dependent mechanism.  Hepatology. 2008;  48(5) 1497-1505
    CrossrefPubMedGoogle Scholar
  • 59 Zhan S S, Jiang J X, Wu J et al.. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo.  Hepatology. 2006;  43(3) 435-443
    CrossrefPubMedGoogle Scholar
  • 60 Watanabe A, Hashmi A, Gomes D A et al.. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9.  Hepatology. 2007;  46(5) 1509-1518
    CrossrefPubMedGoogle Scholar
  • 61 Imaeda A B, Watanabe A, Sohail M A et al.. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome.  J Clin Invest. 2009;  119(2) 305-314
    PubMedGoogle Scholar
  • 62 Gäbele E, Mühlbauer M, Dorn C et al.. Role of TLR9 in hepatic stellate cells and experimental liver fibrosis.  Biochem Biophys Res Commun. 2008;  376(2) 271-276
    CrossrefPubMedGoogle Scholar
  • 63 Torok N J. Apoptotic cell death takes its toll.  Hepatology. 2007;  46(5) 1323-1325
    CrossrefPubMedGoogle Scholar
  • 64 Witek R P, Stone W C, Karaca F G et al.. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.  Hepatology. 2009;  50(5) 1421-1430
    CrossrefPubMedGoogle Scholar
  • 65 Masuoka H C, Guicciardi M E, Gores G J. Caspase inhibitors for the treatment of hepatitis C.  Clin Liver Dis. 2009;  13(3) 467-475
    CrossrefPubMedGoogle Scholar
  • 66 Pockros P J, Schiff E R, Shiffman M L et al.. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.  Hepatology. 2007;  46(2) 324-329
    CrossrefPubMedGoogle Scholar
  • 67 Hoglen N C, Anselmo D M, Katori M et al.. A caspase inhibitor, IDN-6556, ameliorates early hepatic injury in an ex vivo rat model of warm and cold ischemia.  Liver Transpl. 2007;  13(3) 361-366
    CrossrefPubMedGoogle Scholar
  • 68 Baskin-Bey E S, Washburn K, Feng S et al.. Clinical Trial of the Pan-Caspase Inhibitor, IDN-6556, in Human Liver Preservation Injury.  Am J Transplant. 2007;  7(1) 218-225
    CrossrefPubMedGoogle Scholar
  • 69 Ekert P G, Read S H, Silke J et al.. Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die.  J Cell Biol. 2004;  165(6) 835-842
    CrossrefPubMedGoogle Scholar
  • 70 Tait S W, Parsons M J, Llambi F et al.. Resistance to caspase-independent cell death requires persistence of intact mitochondria.  Dev Cell. 2010;  18(5) 802-813
    CrossrefPubMedGoogle Scholar
  • 71 Green D R, Evan G I. A matter of life and death.  Cancer Cell. 2002;  1(1) 19-30
    CrossrefPubMedGoogle Scholar
  • 72 Kaufmann T, Jost P J, Pellegrini M et al.. Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim.  Immunity. 2009;  30(1) 56-66
    CrossrefPubMedGoogle Scholar
  • 73 Zender L, Hutker S, Liedtke C et al.. Caspase 8 small interfering RNA prevents acute liver failure in mice.  Proc Natl Acad Sci U S A. 2003;  100(13) 7797-7802
    CrossrefPubMedGoogle Scholar
  • 74 Yoon J H, Gores G J. Death receptor-mediated apoptosis and the liver.  J Hepatol. 2002;  37(3) 400-410
    CrossrefPubMedGoogle Scholar
  • 75 Lenert P S. Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.  Mediators Inflamm. 2010;  2010 986596
    PubMedGoogle Scholar
  • 76 Santiago-Raber M L, Baudino L, Izui S. Emerging roles of TLR7 and TLR9 in murine SLE.  J Autoimmun. 2009;  33(3-4) 231-238
    CrossrefPubMedGoogle Scholar
  • 77 Fiore G, Piazzolla G, Galetta V, Caccetta L, Schiraldi O, Antonaci S. Liver tissue expression of CD80 and CD95 antigens in chronic hepatitis C: relationship with biological and histological disease activities.  Microbios. 1999;  97(386) 29-38
    PubMedGoogle Scholar
  • 78 Tagashira M, Yamamoto K, Fujio K et al.. Expression of perforin and Fas ligand mRNA in the liver of viral hepatitis.  J Clin Immunol. 2000;  20(5) 347-353
    CrossrefPubMedGoogle Scholar
  • 79 Ibuki N, Yamamoto K, Yabushita K et al.. In situ expression of granzyme B and Fas-ligand in the liver of viral hepatitis.  Liver. 2002;  22(3) 198-204
    PubMedGoogle Scholar
  • 80 Ehrmann Jr J, Galuszková D, Ehrmann J et al.. Apoptosis-related proteins, BCL-2, BAX, FAS, FAS-L and PCNA in liver biopsies of patients with chronic hepatitis B virus infection.  Pathol Oncol Res. 2000;  6(2) 130-135
    CrossrefPubMedGoogle Scholar
  • 81 Pianko S, Patella S, Ostapowicz G, Desmond P, Sievert W. Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection.  J Viral Hepat. 2001;  8(6) 406-413
    CrossrefPubMedGoogle Scholar
  • 82 Tang T J, Kwekkeboom J, Laman J D et al.. The role of intrahepatic immune effector cells in inflammatory liver injury and viral control during chronic hepatitis B infection.  J Viral Hepat. 2003;  10(3) 159-167
    CrossrefPubMedGoogle Scholar
  • 83 Rivero M, Crespo J, Fábrega E et al.. Apoptosis mediated by the Fas system in the fulminant hepatitis by hepatitis B virus.  J Viral Hepat. 2002;  9(2) 107-113
    CrossrefPubMedGoogle Scholar
  • 84 Tagami A, Ohnishi H, Hughes R D. Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose.  Hepatogastroenterology. 2003;  50(51) 742-745
    PubMedGoogle Scholar
  • 85 Ryo K, Kamogawa Y, Ikeda I et al.. Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure.  Am J Gastroenterol. 2000;  95(8) 2047-2055
    CrossrefPubMedGoogle Scholar
  • 86 Tagami A, Ohnishi H, Moriwaki H, Phillips M, Hughes R D. Fas-mediated apoptosis in acute alcoholic hepatitis.  Hepatogastroenterology. 2003;  50(50) 443-448
    PubMedGoogle Scholar
  • 87 Ribeiro P S, Cortez-Pinto H, Solá S et al.. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients.  Am J Gastroenterol. 2004;  99(9) 1708-1717
    CrossrefPubMedGoogle Scholar
  • 88 Fox C K, Furtwaengler A, Nepomuceno R R, Martinez O M, Krams S M. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis.  Liver. 2001;  21(4) 272-279
    PubMedGoogle Scholar
  • 89 Tinmouth J, Lee M, Wanless I R, Tsui F W, Inman R, Heathcote E J. Apoptosis of biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis.  Liver. 2002;  22(3) 228-234
    CrossrefPubMedGoogle Scholar
  • 90 Strand S, Hofmann W J, Grambihler A et al.. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis.  Nat Med. 1998;  4(5) 588-593
    CrossrefPubMedGoogle Scholar
  • 91 Tannapfel A, Kohlhaw K, Ebelt J et al.. Apoptosis and the expression of Fas and Fas ligand (FasL) antigen in rejection and reinfection in liver allograft specimens.  Transplantation. 1999;  67(7) 1079-1083
    CrossrefPubMedGoogle Scholar
  • 92 Strand S, Hofmann W J, Hug H et al.. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—a mechanism of immune evasion?.  Nat Med. 1996;  2(12) 1361-1366
    CrossrefPubMedGoogle Scholar
  • 93 Nagao M, Nakajima Y, Hisanaga M et al.. The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo?.  Hepatology. 1999;  30(2) 413-421
    CrossrefPubMedGoogle Scholar
  • 94 Ito Y, Monden M, Takeda T et al.. The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma.  Br J Cancer. 2000;  82(6) 1211-1217
    CrossrefPubMedGoogle Scholar
  • 95 Ito Y, Takeda T, Umeshita K et al.. Fas antigen expression in hepatocellular carcinoma tissues.  Oncol Rep. 1998;  5(1) 41-44
    PubMedGoogle Scholar
  • 96 Lee S H, Shin M S, Lee H S et al.. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma.  Hum Pathol. 2001;  32(3) 250-256
    CrossrefPubMedGoogle Scholar
  • 97 Okano H, Shiraki K, Inoue H et al.. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma.  Lab Invest. 2003;  83(7) 1033-1043
    CrossrefPubMedGoogle Scholar
  • 98 Miura K, Kodama Y, Inokuchi S et al.. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice.  Gastroenterology. 2010;  139(1) 323-334, e7
    CrossrefPubMedGoogle Scholar

Gregory J GoresM.D. 

Reuben R. Eisenberg Professor of Medicine and Chair, Division of Gastroenterology and Hepatology

College of Medicine, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905

Email: gores.gregory@mayo.edu

      >